All News

infection pneumonia

Pneumocystis Often Lethal in Dermatomyositis

d MedPage Today

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article
T2T.RA_.jpg

High Drug Switching and Low Persistence in Rheumatoid Arthritis

d Jack Cush, MD

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.

Read Article
ACR Clean (Keep)

ACR Comments on JAK Inhibitors and FDA Announcement

d ACR

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article
RheumNow Podcast square

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

d Jack Cush, MD

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article
Have an interest in following healthcare trends and updates on Twitter? Dr. Rachel Tate ( @uptoTate ) shared the top three healthcare hashtags to follow. #RheumNow https://t.co/pnRFNQA5BW https://t.co/5a3CzRtzwR

Links:

Dr. John Cush RheumNow ( View Tweet)
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI https://t.co/SWcedXN2jm

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Comments on JAK Inhibitors and FDA Announcement https://t.co/zDYInRQjTl https://t.co/xu9A8I7Frs

Links:

Dr. John Cush RheumNow ( View Tweet)
Baricitinib & Tofacitinib are effective in COVID-19 pts. These drugs are expensive; baricitinib is $44/tablet, but much lower for generics worldwide. 14 day course of TOFA would be >$1,400 in the US (but $600 in France, $25 in India) https://t.co/r2cn1H2z8i

Links:

Dr. John Cush RheumNow ( View Tweet)

NICE (UK) has recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older. https://t.co/9iLqzo36aD

Links:

Dr. John Cush RheumNow ( View Tweet)

Surveys of 125 clinic patients suggests an improved pt experience by Standardizing appt phone call script, updating appointment package, include a clinic visit prep checklist, to improve pt preparedness and reduce clinic cycle time. https://t.co/5sfBFpag8V

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Causes of DYSGEUSIA (metallic taste): - Antibiotics (clarithromycin, metronidazole tetracycline), Allopurinol, captopril, Lithium, Methazolamide, Metformin, Lunesta and more... heres a video discussion on this. https://t.co/FphprLh1Sf https://t.co/1wkjQxA9UZ https://t.co/kAFaKGiHiG

Links:

Dr. John Cush RheumNow ( View Tweet)
Cytokine Storm Overview Available for Download! https://t.co/XRlx3OJDeR https://t.co/9mGnopNBTs

Links:

Dr. John Cush RheumNow ( View Tweet)
MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization >10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F

Links:

Dr. John Cush RheumNow ( View Tweet)

Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/A8dfCksp3b

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt https://t.co/KHz9LYZVAK

Links:

Dr. John Cush RheumNow ( View Tweet)
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG

Links:

Dr. John Cush RheumNow ( View Tweet)

NOVEL: CRISPR-Cas9 genome editing of stem cells allows sensing of local inflammation & proportionally secrete a programmed anti-inflammatory biologic drug. Stem cells implanted in cartilage can prevent pain and inflammatory damage https://t.co/VNIgnvDU2C

Links:

Dr. John Cush RheumNow ( View Tweet)

MMP13 is one of several key contributors to #OA. Novel research showing the IA depot of nanoparticles w/ small interfering RNAs targeting MMP13 (breaks down type II collagen) can reduce cartilage damage/loss in mouse model of post-traumatic OA https://t.co/3wy6Bdk4o0

Links:

Dr. John Cush RheumNow ( View Tweet)

Differential Dx of immune-mediated necrotizing myopathies (IMNM) - HMGCR & Signal recognition particle Abs; checkpoint inhibitors, anti-Mi2 dermatomyositis, antisynthetase syndr. antimitochondrial Abs, GVHD, SARS-CoV-2 infection https://t.co/hhizx5gAet

Links:

Dr. John Cush RheumNow ( View Tweet)

×